ETF · iShares
BTEE iShares NASDAQ US Biotechnology UCITS ETF
ISIN IE00BDZVHG35London Stock Exchange: BTEEBlackRock, Inc.
- Technology
- ETF
- ISA
- SIPP
- Distributing
Latest close
LSE$10.39
on
- Ongoing charge
- 0.35% a year
- Fund size
- £46.7m
Source: TradingView, as of , at least 15 min delayed
At a glance
As of 30/09/2026, BTEE (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BDZVHG35) closed at $10.39 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 30/09/2026 its total return was +44.4%, or +12.9% after UK CPIH inflation.
Past returns
- 1 year to 30/09/2026
- +49.5%
- +44.8% after inflation (UK CPIH)
- 3 years to 30/09/2026
- +68.0%
- +51.6% after inflation (UK CPIH)
- 5 years to 30/09/2026
- +44.4%
- +12.9% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,444 on 30/09/2026 — about £1,129 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included): 2022 −1.7%, 2023 −0.3%, 2024 +0.3%, 2025 +23.7%; 2026 to 30/09/2026 +25.5%. Returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included) over the 12 months to 30/09/2026: +52.1%; to 30/09/2025: −0.7%; to 30/09/2024: +10.2%; to 30/09/2023: −7.0%; to 30/09/2022: −10.4%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +25.5% | +22.0% | |
| +23.7% | +19.5% | ||
| +0.3% | −3.1% | ||
| −0.3% | −4.3% | ||
| −1.7% | −10.0% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +52.1% | Not available |
| from | −0.7% | −4.5% |
| from | +10.2% | +7.4% |
| from | −7.0% | −12.6% |
| from | −10.4% | −17.7% |
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , inflation: ONS CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
18.9%over 5 years
| 1 year | 18.7% |
|---|---|
| 3 years | 19.5% |
| 5 years | 18.9% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since October 2021
- −23.7%
- From to
- Lowest 12-month return
- −22.0%
- 12 months to
- Highest 12-month return
- +60.0%
- 12 months to
- Below its highest weekly close since October 2021
- 0.0%
- High of , latest
In words: Volatility of iShares NASDAQ US Biotechnology UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 18.7% over 1 year, 19.5% over 3 years, 18.9% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF since October 2021, in pounds: −23.7% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price only, income paid out not included) since January 2021 was −22.0% (12 months to 18/02/2022); the highest was +60.0% (12 months to 03/07/2026). On 30/09/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF was at its highest weekly close since October 2021, in pounds.
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , price only — income paid out is not included
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.35%
- a year
- On £10,000
- £35
- a year, roughly
- Over five years
- £174
- of £10,000, before growth
- 18 charge less
- 8 the same
- 92 charge more
Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year, as of 01/10/2026: 92 of the 118 other technology funds charge more, 8 the same and 18 less (share classes counted once).
Source: Fund ongoing charges via TradingView, as of
A lower charge is not a promise of a higher return: what the fund holds matters more. Charges are the fund’s own published ongoing charges figure.
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2018.
It tracks the NASDAQ / Biotechnology.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is paid out to holders as cash, usually a few times a year.
Technology: Software, chips, AI and other tech companies. One sector only, so prices can move more than a broad fund.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- BTEE
- ISIN
- IE00BDZVHG35
- Provider
- iShares
- Tracks
- NASDAQ / Biotechnology
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Distributing, paid semi-annual
- Income is paid out to holders as cash, usually a few times a year.
- Ongoing charge
- 0.35% a year · about £35 on £10,000
- Fund size
- £46.7m
- Launched
- Domicile
- Ireland
- Can be held in
- ISA and SIPP
- Currency hedged
- No
- Price currency
- USD
- Category
- Technology
Price chart
Since 31/07/2026, the closing price went from $9.29 on 31/07/2026 to $10.39 on 30/09/2026 (+11.7%). The lowest close shown was $9.29 on 31/07/2026 and the highest $10.60 on 27/08/2026.
Chart: closing prices we have recorded since 31/07/2026. Price only — income paid out is not included, so the line can end below the total return above.
Source: TradingView, as of , at least 15 min delayed
Five years of prices, and after inflation
10 weekly closes, from 31/07/2026 to 30/09/2026. The same history in September 2026 pounds, adjusted with ONS CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
Funds tracking the same index
3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (30/09/2026).
| Fund | 1 year | 5 years |
|---|---|---|
| Invesco NASDAQ Biotech UCITS ETFAccumulating · 0.40% a year | +46.1% | +35.2% |
| iShares NASDAQ US Biotechnology UCITS ETFThis fundDistributing · 0.35% a year | +49.5% | +44.4% |
| iShares NASDAQ US Biotechnology UCITS ETFAccumulating · 0.35% a year | +50.0% | +45.9% |
Source: TradingView reported returns and fund ongoing charges, as of
Read more:Index fundsTracking differenceHow funds are compared
Other versions of this fund
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1, 3 and 5 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 248 rolling 12-month returns since January 2021, and of 144 rolling three-year returns, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 3 largest falls since October 2021, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Rank among similar funds
Rank by total return over 1, 3 and 5 years among up to 11 technology funds investing in the US, not currency-hedged, highest first.
ProMoves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core S&P 500 UCITS ETF, over the three years to 30/09/2026 (151 weeks).
Pro
Pro — currently by invitation
Pro includes the rank among similar funds and moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of BTEE?
The ongoing charge of BTEE is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year, as of 01/10/2026: 92 of the 118 other technology funds charge more, 8 the same and 18 less (share classes counted once).
What does BTEE track?
BTEE tracks the NASDAQ / Biotechnology.
Is BTEE accumulating or distributing?
BTEE is distributing: income is paid out to holders as cash, usually a few times a year. It pays out semi-annual.
What is the ISIN of BTEE?
The ISIN of BTEE is IE00BDZVHG35. An ISIN identifies one exact share class of a fund; BTEE is its ticker on the London Stock Exchange.
What were BTEE’s returns in each of the last five years?
Calendar-year returns of BTEE in pounds (price only, income paid out not included): 2022 −1.7%, 2023 −0.3%, 2024 +0.3%, 2025 +23.7%; 2026 to 30/09/2026 +25.5%. Past performance is not a guide to future returns.
How has BTEE done after inflation?
Over the five years to 30/09/2026 BTEE’s total return was +44.4%, or +12.9% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- IITUiShares S&P 500 Information Technology Sector UCITS ETF0.15% a year · £12bn
- XAIXXtrackers Artificial Intelligence & Big Data UCITS ETF0.35% a year · £5.4bn
- SMGBVanEck Semiconductor UCITS ETF Accum A USD0.35% a year · £5.4bn
- XXTWXtrackers MSCI World Information Technology UCITS ETF0.25% a year · £3.9bn
- SEMIiShares MSCI Global Semiconductors UCITS ETF AccumUSD0.35% a year · £3.7bn
- RBTXiShares Automation & Robotics UCITS ETF0.40% a year · £3.1bn
- ISPYCyber Security UCITS ETF0.73% a year · £2.3bn
- 0MVVAmundi MSCI World Information Technology UCITS ETF EUR ACC0.30% a year · £1.9bn
Sources and dates
- Prices
- London Stock Exchange closes via TradingView, at least 15 minutes delayed, latest
- Returns
- TradingView reported returns (net asset value with income reinvested where available)
- Calendar years, risk
- Fundology, from recorded closes (weekly history from the data vendor where our record is short)
- Inflation
- ONS CPIH, latest month used August 2026
- Charges
- The fund’s ongoing charges figure, via TradingView
- Identity
- FCA Financial Instruments Reference Data System (FIRDS) and the issuer
- Fund size
- TradingView, converted to pounds at the latest ECB reference rate
Methodology:Data sourcesReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.